ArticleAmerican journal of translational research2026
Effectiveness and multidimensional mechanisms of close-to-bone needling in knee osteoarthritis: a randomized controlled trial.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the clinical efficacy of close-to-bone needling (CBN) in patients with knee osteoarthritis (KOA) and to explore its underlying mechanisms.
methodsSeventy patients with KOA were randomized to receive either CBN (n=35) or oral celecoxib (Drug Group, DG, n=35) for a 4-week intervention period, followed by a 2-week follow-up. Additionally, 35 healthy controls (HC) were enrolled. Clinical outcomes were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Index of Severity for Osteoarthritis of the Knee (ISOA), and the 36-Item Short Form Health Survey (SF-36). Structural alterations were evaluated by magnetic resonance imaging (MRI)-based Whole-Organ Magnetic Resonance Imaging Score (WORMS) and musculoskeletal ultrasound. Molecular changes were assessed by quantifying plasma and synovial fluid levels of miR-140, miR-30, interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α). Neural correlates were assessed via resting-state electroencephalography (EEG), including spectral power analysis and graph-theoretical analysis of brain network characteristics.
resultsCompared with the DG group, the CBN group showed significantly greater overall clinical efficacy at 6 weeks (P<0.05), with greater improvements in WOMAC, ISOA, and SF-36 scores, as well as greater reductions in cartilage degeneration, synovial thickening, and joint effusion (P<0.05). Furthermore, CBN produced stronger modulatory effects on miR-140, miR-30, IL-1β, and TNF-α levels (P<0.05). EEG analysis revealed reduced Delta and Theta power, increased Alpha, Beta, and Gamma power in frontoparietal regions, and normalization of abnormal prefrontal connectivity patterns in the Theta and Gamma frequency bands (P<0.05).
conclusionCBN represents an effective non-pharmacological intervention for KOA, with advantages over celecoxib in symptom relief, joint structure improvement, molecular regulation, and central neural normalization. The proposed "brain-molecule-clinic" assessment framework provides multidimensional evidence supporting the potential mechanisms of acupuncture-based interventions in KOA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.